BackMirum Pharmaceuticals Overview
Mirum Pharmaceuticals Inc

Mirum Pharmaceuticals Target Price

Analysts' average 12-month price target for Mirum Pharmaceuticals is $140.

Get informed when a big investor buys or sells

+ Follow

Share Price

$91.39

Average Target Price

$139.5052.6% upside

8 analysts in the last 4 months

High: $150 | Low: $123

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-08-27UBS$13749.9% upsideOpen
2026-08-06Robert W. Baird$12334.6% upsideOpen
2026-08-06Morgan Stanley$13749.9% upsideOpen
2026-08-06RBC Capital$13547.7% upsideOpen
2026-08-06H.C. WainwrightSwayampakula Ramakanth$14053.2% upsideOpen
2026-07-07RBC CapitalLisa Walter$14861.9% upsideOpen
2026-06-15CLSA$14659.8% upsideOpen
2026-06-11Morgan Stanley$15064.1% upsideOpen
2026-05-19Wolfe Research$14558.7% upsideOpen
2026-05-07RBC CapitalJoe Kim$14255.4% upsideOpen
2026-05-07Raymond JamesRyan Deschner$16580.5% upsideOpen
2026-05-07H.C. Wainwright$185102.4% upsideOpen
2026-05-07Evercore ISI$13851% upsideOpen
2026-05-07Stifel Nicolaus$13648.8% upsideOpen
2026-05-07Robert W. Baird$12941.2% upsideOpen
2026-05-05Morgan Stanley$14053.2% upsideOpen
2026-05-04H.C. Wainwright$17591.5% upsideOpen
2026-04-28Robert W. BairdBrian Skorney$11222.6% upsideOpen
2026-04-27H.C. Wainwright$15064.1% upsideOpen
2026-03-04Evercore ISIGavin Clark-Gartner$12637.9% upsideOpen
2026-02-26Leerink PartnersMani Foroohar$11829.1% upsideOpen
2026-02-26RBC CapitalJoe Kim$12840.1% upsideOpen
2026-02-17RBC Capital$13042.2% upsideOpen
2026-01-26H.C. Wainwright$13042.2% upsideOpen
2026-01-20Evercore ISI$10110.5% upsideOpen
2026-01-13H.C. Wainwright$10211.6% upsideOpen
2026-01-12Robert W. Baird$954% upsideOpen
2025-12-19UBS$14053.2% upsideOpen
2025-12-11Raymond JamesSteven Seedhouse$11020.4% upsideOpen
2025-12-10Leerink Partners$1009.4% upsideOpen
2025-12-09Morgan StanleyMichael Ulz$954% upsideOpen
2025-12-08Evercore ISI$942.9% upsideOpen
2025-12-08Robert W. BairdBrian Skorney$883.7% downsideOpen
2025-12-08Cantor Fitzgerald$13042.2% upsideOpen
2025-11-05Cantor Fitzgerald$954% upsideOpen
2025-11-05H.C. WainwrightSwayampakula Ramakanth$8111.4% downsideOpen
2025-11-05JMP Securities$954% upsideOpen
2025-10-16Morgan Stanley$8111.4% downsideOpen
2025-08-11Stifel NicolausJames Condulis$892.6% downsideOpen
2025-08-07JMP SecuritiesJonathan Wolleben$8111.4% downsideOpen
2024-11-12Stifel NicolausDae Gon Ha$7023.4% downsideOpen
2024-08-08Robert W. BairdBrian Skorney$4451.9% downsideOpen
2024-06-17Evercore ISIGavin Clark-Gartner$6232.2% downsideOpen
2024-06-17Morgan StanleyMichael E Ulz$5737.6% downsideOpen
2024-06-17H.C. WainwrightEd Arce$6627.8% downsideOpen
2024-06-17Robert W. BairdBrian Skorney$3957.3% downsideOpen
2024-05-23Cantor FitzgeraldJoshua Schimmer$4550.8% downsideOpen
2024-04-16Stifel NicolausDae Gon Ha$4847.5% downsideOpen
2024-03-14H.C. WainwrightEd Arce$5836.5% downsideOpen
2023-01-10Leerink Partners$3957.3% downsideOpen

Mirum Pharmaceuticals (MIRM) FAQ

Mirum Pharmaceuticals's target price stands at $140. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

The Street's average target of $140 for MIRM implies 52.6% upside versus today's price ($91.39). Positive implied upside usually reflects optimism on growth or margins, while a large downside can signal valuation or fundamental concerns. Check recommendation mix and recent target changes for more context.

The history chart shows how Mirum Pharmaceuticals's target price evolved across reporting periods, while the comparison chart places MIRM next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, target price is commonly used to spot outliers. Mirum Pharmaceuticals's reading of $140 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.